Join our daily newsletter At The Bell to receive exclusive market insights
- PYC Therapeutics (PYC) adds a third drug program for the treatment of Phelan McDermid Syndrome (PMS) to its clinical pipeline
- This new program follows in-vitro test results of PYC’s RNA therapeutic demonstrating an ability to correct the faulty gene expression responsible for causing PMS
- PYC says the program demonstrates the scalability of its platform technology into target tissues beyond the eye
- The new program will now progress into testing in patient-derived and animal models
- Shares in PYC are trading grey at 7 cents at 3:42 pm AEST
PYC Therapeutics (PYC) has added a third drug program for the treatment of Phelan McDermid Syndrome (PMS) to its clinical pipeline.
The new program will focus on the treatment of Phelan McDermid Syndrome (PMS), a neurodevelopmental disorder caused by a deficiency of a gene known as SHANK3 in neuronal cells in the brain, using PYC’s RNA therapeutic.
It follows in-vitro test results of the product that demonstrated an ability to correct the faulty gene expression responsible for causing PMS.
The company said it had designed and validated an RNA therapeutic capable of increasing SHANK3 expression in cells by approximately two- to threefold, establishing a development path in the treatment of central nervous system (CNS) diseases.
The new pipeline addition represents the company’s first program in the CNS, which it said demonstrated the scalability of its platform technology into target tissues beyond the eye.
To advance the program, PYC has partnered with the PMS Foundation (PMSF) and its research clinicians to push for the first disease-modifying approach for the treatment of PMS.
The new program will now progress into testing in patient-derived and animal models.
Shares in PYC were trading grey at 7 cents at 3:42 pm AEST.
